Welcome to...The UCLA Endocrine Surgical Unit
 

Schedule an Appointment
Endocrine Home
About Us
Our Expert Team
Our Services
First Visit for Patients
Patient Education
Scar Gallery
For Referring Physicians
Distance Surgery Program
International Patients
Insurance Questions
Map-Directions-Parking
Contact Us
Patient Experiences
Endocrine Resources
Site Map

UCLA Health System


Schedule an Appointment


Parathyroid News Feeds

Worldwide News: View Endocrine News | View Parathyroid News


Tue, 16 Sep 2014 00:03:27 GMT
• NPS Pharmaceuticals' Natpara Gets Positive FDA Panel Vote - Analyst Blog - NASDAQ

NPS Pharmaceuticals' Natpara Gets Positive FDA Panel Vote - Analyst Blog
NASDAQ
NPS Pharma's candidate was recommended for long-term use to treat patients suffering from hypoparathyroidism, a rare disease caused by the deficiency/absence of parathyroid hormone, by 8 of the 13 panel members. The positive opinion rendered by the ...

and more »

Mon, 15 Sep 2014 16:48:56 GMT
• News Review - NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) , J C Penney ... - Techsonian (press release)

News Review - NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) , J C Penney ...
Techsonian (press release)
... Drugs Advisory Committee voted 8 to 5 that the available data support the approval of NatparaŽ (rhPTH [1-84]) for the long-term treatment of Hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of parathyroid hormone, or PTH.

and more »

Sun, 14 Sep 2014 21:00:00 GMT
• FDA Panel Votes For NPS Pharma's Natpara For Hypoparathyroidism Treatment - NASDAQ

FDA Panel Votes For NPS Pharma's Natpara For Hypoparathyroidism Treatment
NASDAQ
Hypoparathyroidism is a rare condition in which the parathyroid glands fail to produce sufficient amounts of parathyroid hormone (PTH) or where PTH lacks biologic activity. PTH plays a central role in a variety of critical physiological functions in the body.

and more »

Sun, 14 Sep 2014 21:00:00 GMT
• FDA Committee Backs Approval of Natpara for Treatment of Hypoparathyroidism - Drug Discovery & Development

Drug Discovery & Development

FDA Committee Backs Approval of Natpara for Treatment of Hypoparathyroidism
Drug Discovery & Development
"As a bioengineered replacement therapy targeting the underlying cause of the disorder, Natpara has been shown in clinical studies to maintain serum calcium while demonstrating similar physiologic effects to the native parathyroid hormone. We look forward ...

and more »

Sat, 13 Sep 2014 14:54:31 GMT
• Natpara Recommended by FDA Panel for Hyperparathyroidism - Medscape

Natpara Recommended by FDA Panel for Hyperparathyroidism
Medscape
Recombinant human parathyroid hormone (rhPTH[1-84]) (Natpara, NPS Pharmaceuticals) has been recommended for approval for the long-term treatment of hypoparathyroidism by a Food and Drug Administration (FDA) advisory committee. On September ...



Worldwide "Parathyroid" News Courtesy of Google News